Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based based » based case (Expand Search), based basis (Expand Search), ranked based (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based based » based case (Expand Search), based basis (Expand Search), ranked based (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
101
-
102
-
103
-
104
-
105
LSPC treatment decreases neuropathology in prion-infected mice.
Published 2019“…<p>Immunohistochemistry (IHC) of brain sections through the (A) cerebellum and (B) hippocampus in infected and uninfected mice reveal that (A) while we observed no difference in cerebellar PrP<sup>Res</sup> accumulation among infected untreated, non-responder or responder mice, both GFAP stain intensity, a measure of astrogliosis, and vacuolation, a hallmark of prion-mediated neurodegeneration, were significantly decreased in LSPC responder mice. …”
-
106
Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA....
Published 2025“…Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. …”
-
107
-
108
-
109
-
110
The slope for all significant factors on the number of steps before a fall across all three speeds.
Published 2022Subjects: -
111
Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.
Published 2024Subjects: -
112
Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.
Published 2024Subjects: -
113
-
114
-
115
-
116
Conditioned pain modulation (CPM) score based on OPRM1 genotype in the study group.
Published 2022Subjects: -
117
-
118
Subgroup analysis of BUN based on pump type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
119
Subgroup analysis of BUN based on surgery type.
Published 2025“…The analysis showed that pulsatile perfusion led to a significant decrease in creatinine level [MD = −0.14, 95% CI (−0.24, −.04), P < 0.004], lactate level [MD = −8.21, 95% CI (−13.16, −3.25), P < 0.001], hospital stay [MD = −1.38, 95% CI (−2.51, −0.25), P = 0.016], ICU stay [MD = −0.47, 95% CI (−0.82, −0.13), P = 0.007], intubation time [MD = −3.73, 95% CI (−5.42, −2.04), P < 0.001], and increase in creatinine clearance [MD = 10.08, 95% CI (3.36, 16.80), P < 0.003]. …”
-
120
Column-based Technology for CD9-HPLC Immunoaffinity Isolation of Serum Extracellular Vesicles
Published 2021“…Herein we have developed a column-based CD9-antibody-immobilized high-performance liquid chromatography immunoaffinity chromatography(CD9-HPLC-IAC) technology for EV isolation from a microliter scale of serum for downstream proteomic analysis. …”